Cart is empty Eisai Co.’s breakthrough Alzheimer’s drug—the first to show it slows the brain-destroying disease—is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.
Eisai Co.’s breakthrough Alzheimer’s drug—the first to show it slows the brain-destroying disease—is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.
Leave A Comment